{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:15:16Z","timestamp":1780665316520,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T00:00:00Z","timestamp":1702684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["Special Interest Project 19-009 with Emory University"],"award-info":[{"award-number":["Special Interest Project 19-009 with Emory University"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["Special Interest Project 19-009 with Emory University"],"award-info":[{"award-number":["Special Interest Project 19-009 with Emory University"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["Special Interest Project 19-009 with Emory University"],"award-info":[{"award-number":["Special Interest Project 19-009 with Emory University"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11764-023-01509-8","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T01:01:46Z","timestamp":1702688506000},"page":"871-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Health-related quality of life among prostate cancer survivors with metastatic disease and non-metastatic disease and men without a cancer history in the USA"],"prefix":"10.1007","volume":"19","author":[{"given":"Zhiyuan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei Sylvia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Horn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatus U.","family":"Ekwueme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Robin","family":"Yabroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"key":"1509_CR1","unstructured":"U.S. Cancer Statistics Working Group. U.S. Cancer statistics data visualizations tool, based on 2022 submission data (1999-2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; https:\/\/www.cdc.gov\/cancer\/dataviz, released in November 2023. Accessed."},{"key":"1509_CR2","unstructured":"Centers for Disease Control and Prevention. Prostate cancer incidence by age and stage at diagnosis, United States\u20142001\u25002019. USCS data brief, no 34. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2023."},{"issue":"1","key":"1509_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin."},{"key":"1509_CR4","unstructured":"Cancer Statistics At a Glance. Cancer statistics home. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/cancer\/uscs\/. Accessed March 10, 2023."},{"key":"1509_CR5","unstructured":"The American Cancer Society medical and editorial content team. Survival rates for prostate cancer. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html#references. Accessed Oct 10, 2022."},{"issue":"1","key":"1509_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/cancers14010147","volume":"14","author":"A Kretschmer","year":"2021","unstructured":"Kretschmer A, van den Bergh RCN, Martini A, et al. Assessment of health-related quality of life in patients with advanced prostate cancer-current state and future perspectives. Cancers (Basel). 2021;14(1):147.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"1509_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.urolonc.2019.07.005","volume":"37","author":"R Mager","year":"2019","unstructured":"Mager R, Savko O, B\u00f6hm K, et al. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Urol Oncol. 2019;37(12):999\u20131005.","journal-title":"Urol Oncol."},{"key":"1509_CR8","unstructured":"Prostate Cancer Treatment (PDQ\u00ae)\u2013Health professional version. National Cancer Institute. https:\/\/www.cancer.gov\/types\/prostate\/hp\/prostate-treatment-pdq. Accessed Nov 10, 2022."},{"issue":"2","key":"1509_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","volume":"8","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, W\u00fcrnschimmel C, Nocera L, et al. Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus. 2022;8(2):399\u2013408.","journal-title":"Eur Urol Focus."},{"key":"1509_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","volume":"5","author":"D Menges","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S, et al. Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol. 2022;5:605\u201316.","journal-title":"Eur Urol Oncol."},{"key":"1509_CR11","unstructured":"HRQOL Concepts. Health-related quality of life (HRQOL). Centers for disease control and prevention. https:\/\/www.cdc.gov\/hrqol\/concept.htm. Accessed Nov 11, 2022."},{"key":"1509_CR12","unstructured":"Centers for Disease Control and Prevention. Measuring healthy days: population assessment of health-related quality of life. 2000."},{"key":"1509_CR13","doi-asserted-by":"publisher","first-page":"3565238","DOI":"10.1155\/2020\/3565238","volume":"2020","author":"M J\u00f6rling","year":"2020","unstructured":"J\u00f6rling M, Rutzner S, Hecht M, Fietkau R, Distel LV. Deterioration of health-related quality of life scores under treatment predicts longer survival. Biomed Res Int. 2020;2020:3565238.","journal-title":"Biomed Res Int."},{"issue":"1","key":"1509_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1745-6215-15-49","volume":"15","author":"RC Macefield","year":"2014","unstructured":"Macefield RC, Jacobs M, Korfage IJ, et al. Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials. 2014;15(1):49.","journal-title":"Trials."},{"issue":"5","key":"1509_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.eururo.2015.06.007","volume":"68","author":"AK Morgans","year":"2015","unstructured":"Morgans AK, van Bommel ACM, Stowell C, et al. Development of a Standardized set of patient-centered outcomes for advanced prostate cancer: an international effort for a unified approach. Eur Urol. 2015;68(5):891\u20138.","journal-title":"Eur Urol."},{"key":"1509_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1477-7525-2-33","volume":"2","author":"N Jones 3rd","year":"2004","unstructured":"Jones N 3rd, Jones SL, Miller NA. The Medicare Health Outcomes Survey program: overview, context, and near-term prospects. Health Qual Life Outcomes. 2004;2:33.","journal-title":"Health Qual Life Outcomes."},{"key":"1509_CR17","unstructured":"History of the SEER-MHOS Linked Data Resource. Data & Tools. Healthcare delivery research program. Division of Cancer Contrl and Population Sciences. NCI. . https:\/\/healthcaredelivery.cancer.gov\/seer-mhos\/overview\/history.html. Accessed Oct, 21, 2022."},{"key":"1509_CR18","unstructured":"Compare Original Medicare & Medicare Advantage. . https:\/\/www.medicare.gov\/basics\/get-started-with-medicare\/get-more-coverage\/your-coverage-options\/compare-original-medicare-medicare-advantage. Accessed Nov 27, 2023."},{"key":"1509_CR19","unstructured":"NCI Dictionary of Cancer Terms. National Cancer Institute. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/primary-cancer Accessed Jan 7, 2023."},{"issue":"1","key":"1509_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11136-008-9418-2","volume":"18","author":"AJ Selim","year":"2009","unstructured":"Selim AJ, Rogers W, Fleishman JA, et al. Updated US population standard for the Veterans RAND 12-item Health Survey (VR-12). Qual Life Res. 2009;18(1):43\u201352.","journal-title":"Qual Life Res."},{"issue":"10","key":"1509_CR21","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s11606-015-3453-9","volume":"30","author":"BD Schalet","year":"2015","unstructured":"Schalet BD, Rothrock NE, Hays RD, et al. Linking Physical and Mental Health Summary Scores from the Veterans RAsssND 12-Item Health Survey (VR-12) to the PROMIS(\u00ae) Global Health Scale. J Gen Intern Med. 2015;30(10):1524\u201330.","journal-title":"J Gen Intern Med."},{"key":"1509_CR22","unstructured":"SEER-MHOS: Algorithms to Recode the 8 VR-12 Scales to Match SF-36. Boston University Bridge program. . http:\/\/healthcaredelivery.cancer.gov\/seer-mhos\/program\/recode.html. Accessed Oct 12, 2022."},{"key":"1509_CR23","unstructured":"Prostate-Specific Antigen (PSA) Test. National Cancer Institute. . https:\/\/www.cancer.gov\/types\/prostate\/psa-fact-sheet. Accessed Nov 10, 2023."},{"issue":"8","key":"1509_CR24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","volume":"118","author":"GH Guyatt","year":"1993","unstructured":"Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118(8):622\u20139.","journal-title":"Ann Intern Med."},{"issue":"10","key":"1509_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11934-019-0924-2","volume":"20","author":"J Shevach","year":"2019","unstructured":"Shevach J, Weiner A, Morgans AK. Quality of life-focused decision-making for prostate cancer. Curr Urol Rep. 2019;20(10):57.","journal-title":"Curr Urol Rep."},{"key":"1509_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1146\/annurev-med-050710-134421","volume":"63","author":"AJ Vickers","year":"2012","unstructured":"Vickers AJ, Roobol MJ, Lilja H. Screening for prostate cancer: early detection or overdetection? Annu Rev Med. 2012;63:161\u201370.","journal-title":"Annu Rev Med."},{"issue":"18","key":"1509_CR27","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","volume":"34","author":"RC Chen","year":"2016","unstructured":"Chen RC, Rumble RB, Loblaw DA, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline endorsement. J Clin Oncol. 2016;34(18):2182\u201390.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1509_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/iju.14202","volume":"27","author":"T Kato","year":"2020","unstructured":"Kato T, Sugimoto M. Quality of life in active surveillance for early prostate cancer. Int J Urol. 2020;27(4):296\u2013306.","journal-title":"Int J Urol."},{"issue":"2","key":"1509_CR29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.juro.2016.02.2972","volume":"196","author":"KN Pham","year":"2016","unstructured":"Pham KN, Cullen J, Hurwitz LM, et al. Prospective quality of life in men choosing active surveillance compared to those biopsied but not diagnosed with prostate cancer. J Urol. 2016;196(2):392\u20138.","journal-title":"J Urol."},{"issue":"15","key":"1509_CR30","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425\u201337.","journal-title":"N Engl J Med."},{"issue":"6","key":"1509_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.eururo.2017.06.035","volume":"72","author":"M Lardas","year":"2017","unstructured":"Lardas M, Liew M, van den Bergh RC, et al. Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review. Eur Urol. 2017;72(6):869\u201385.","journal-title":"Eur Urol."},{"key":"1509_CR32","unstructured":"Hormone Therapy for Prostate Cancer. Treating prostate cancer. Prostate Cancer. Cancer A-Z. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/treating\/hormone-therapy.html. Accessed Nov 19, 2022."},{"key":"1509_CR33","unstructured":"Prostate Cancer Treatment (PDQ\u00ae)\u2013Health Professional Version. Prostate cancer. Cancer Types. . https:\/\/www.cancer.gov\/types\/prostate\/hp\/prostate-treatment-pdq#_2938. Accessed Nov 19, 2022."},{"issue":"11","key":"1509_CR34","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","volume":"36","author":"AK Morgans","year":"2018","unstructured":"Morgans AK, Chen YH, Sweeney CJ, et al. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol. 2018;36(11):1088\u201395.","journal-title":"J Clin Oncol."},{"issue":"10","key":"1509_CR35","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/pon.3288","volume":"22","author":"T LeMasters","year":"2013","unstructured":"LeMasters T, Madhavan S, Sambamoorthi U, Kurian S. A population-based study comparing HRQoL among breast, prostate, and colorectal cancer survivors to propensity score matched controls, by cancer type, and gender. Psycho-Oncol. 2013;22(10):2270\u201382.","journal-title":"Psycho-Oncol"},{"issue":"5","key":"1509_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/NCC.0000000000000432","volume":"40","author":"L Zajdlewicz","year":"2017","unstructured":"Zajdlewicz L, Hyde MK, Lepore SJ, Gardiner RA, Chambers SK. Health-related quality of life after the diagnosis of locally advanced or advanced prostate cancer: a longitudinal study. Cancer Nurs. 2017;40(5):412\u20139.","journal-title":"Cancer Nurs"},{"issue":"4","key":"1509_CR37","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.euf.2020.01.017","volume":"7","author":"A Kretschmer","year":"2021","unstructured":"Kretschmer A, Ploussard G, Heidegger I, et al. Health-related quality of life in patients with advanced prostate cancer: a systematic review. Eur Urol Focus. 2021;7(4):742\u201351.","journal-title":"Eur Urol Focus."},{"key":"1509_CR38","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/1471-2407-9-296","volume":"9","author":"M Pinkawa","year":"2009","unstructured":"Pinkawa M, Fischedick K, Gagel B, et al. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer. 2009;9:296.","journal-title":"BMC Cancer."},{"issue":"3","key":"1509_CR39","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1743-6109.2007.00722.x","volume":"5","author":"N Bhojani","year":"2008","unstructured":"Bhojani N, Perrotte P, Jeldres C, et al. The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screening. J Sex Med. 2008;5(3):668\u201376.","journal-title":"J Sex Med."},{"issue":"7","key":"1509_CR40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jama.2009.1198","volume":"302","author":"M Bakitas","year":"2009","unstructured":"Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. Jama. 2009;302(7):741\u20139.","journal-title":"Jama."},{"issue":"17","key":"1509_CR41","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1200\/JCO.2006.09.2627","volume":"25","author":"JS Temel","year":"2007","unstructured":"Temel JS, Jackson VA, Billings JA, et al. Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J Clin Oncol. 2007;25(17):2377\u201382.","journal-title":"J Clin Oncol."},{"issue":"14","key":"1509_CR42","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1001\/jama.299.14.1698","volume":"299","author":"C Zimmermann","year":"2008","unstructured":"Zimmermann C, Riechelmann R, Krzyzanowska M, Rodin G, Tannock I. Effectiveness of specialized palliative care: a systematic review. Jama. 2008;299(14):1698\u2013709.","journal-title":"Jama."},{"issue":"1","key":"1509_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12904-018-0381-6","volume":"17","author":"M Holm","year":"2018","unstructured":"Holm M, Doveson S, Lindqvist O, Wennman-Larsen A, Fransson P. Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data. BMC Palliat Care. 2018;17(1):126.","journal-title":"BMC Palliat Care."},{"issue":"2","key":"1509_CR44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/1049909119864576","volume":"37","author":"NA Mistry","year":"2020","unstructured":"Mistry NA, Raza SJ, Siddiqui SA. Analysis of inpatient palliative care consultations for patients with metastatic prostate cancer. Am J Hospice Pall Med \u00ae. 2020;37(2):136\u201341.","journal-title":"Am J Hospice Pall Med \u00ae"},{"key":"1509_CR45","doi-asserted-by":"crossref","unstructured":"Espinosa Ben\u00edtez QL, Jim\u00e9nez Ayala VG, Bautista RIA. Palliative care in elderly adults with prostate cancer. Sapienza: Int J Interdiscip Stud. 2022;3(8):93-104.","DOI":"10.51798\/sijis.v3i8.565"},{"key":"1509_CR46","unstructured":"Freed M, Biniek JF, Damico A, Neuman T. Medicare advantage in 2022: enrollment update and key trends. Kaiser. https:\/\/www.kff.org\/medicare\/issue-brief\/medicare-advantage-in-2022-enrollment-update-and-key-trends\/. Accessed Nov 11, 2022."},{"key":"1509_CR47","unstructured":"Jacobson G, Cicchiello A, Sutton JP, Shah A. Medicare advantage vs. traditional medicare: how do beneficiaries\u2019 characteristics and experiences differ? . https:\/\/www.commonwealthfund.org\/publications\/issue-briefs\/2021\/oct\/medicare-advantage-vs-traditional-medicare-beneficiaries-differ. Accessed Nov 19, 2022."},{"key":"1509_CR48","unstructured":"Beneficiary experience, affordability, utilization, and quality in medicare advantage and traditional medicare: a review of the literature. https:\/\/www.kff.org\/medicare\/report\/beneficiary-experience-affordability-utilization-and-quality-in-medicare-advantage-and-traditional-medicare-a-review-of-the-literature\/. Accessed Nov 27, 2023."},{"key":"1509_CR49","unstructured":"SEER acknowledgment of treatment data limitations. https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2022\/treatment-limitations-nov2022.html. Accessed."}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-023-01509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-023-01509-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-023-01509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:56:06Z","timestamp":1747288566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-023-01509-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,16]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1007\/s11764-023-01509-8","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,16]]},"assertion":[{"value":"13 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Dr. Yabroff serves on the Flatiron Health Equity Advisory Board and has received honoraria from the National Comprehensive Cancer Network. Dr. Arif H. Kamal reports personal fees from Homebase Medical outside the submitted work and is chief executive officer of Prepped Health. All other authors have no conflict of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, Emory University, or the American Cancer Society.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}